IKOULA
9.12.2021 10:02:06 CET | Business Wire | Press release
The French specialist in web hosting, dedicated servers and cloud computing IKOULA announced a joint case study with the leading open-source cloud management software CloudStack. For the management of their cloud environment, IKOULA decided to choose the open-source way by combining the power of CloudStack with the simplicity of the open-source hypervisor XCP-ng. Тhe turnkey combination was carefully selected following the long-term company strategy to guarantee a constant product evolution, reliability and simplicity for their customers. As a result, IKOULA is now among the most innovative cloud and managed services providers in Europe, with an extensive portfolio of cloud solutions. Moreover, a large number of customers use their CloudStack-orchestrated infrastructure to deploy memory-oriented and storage-oriented VMs or Kubernetes clusters.
The cloud and hosting market is one of the most competitive in the tech industry. Companies need to constantly innovate, be creative, offer exceptional service quality and support while keeping a competitive price. Choosing an open-source technology stack is a strategic decision taken by IKOULA. They eliminate all vendor lock-ins and ensure the company has full control over their infrastructure by being open-source. Other significant benefits are the easy management of extensive infrastructure, guaranteed reliability, and seamless scalability.
“It is essential for us as a hosting company to know exactly what is running on our servers. This is a decisive advantage in terms of security.
We decided to go with open-source solutions, as they deliver the reliability and flexibility we need. When it comes to debugging issues, we can quickly look in the code and fix it or ask the community for help on the error. CloudStack and XCP-ng have an active and growing community and constantly evolving products, which is a huge benefit”, said Joaquim Dos Santos, R&D Director at Ikoula.
CloudStack and XCP-ng also give a financial advantage to IKOULA, which is extremely important in their market segment. According to their team, operating XCP-ng and CloudStack results in greatly reduced costs than other solutions. They have also greatly reduced their reliance on 3rd parties to help maintain their environment.
At this stage, IKOULA manages a large CloudStack environment with 100+ hosts in 8 different zones and 6600+ customers using it. They can make live updates and upgrades of the system without any service interruptions for the end-users. Among the most valuable CloudStack features for them are the multi-tenancy of the solution, its scalability and the power to easily manage hundreds of hosts and thousands of VMs.
About IKOULA
Pioneer of the French Cloud since 1998, IKOULA has its own Datacenters in France, as well as two subsidiaries, in Spain and in the Netherlands. Because people are part of its DNA, IKOULA maintains a close relationship with its customers, and provides them with teams of experts available 24/7, to advise and support them in their activities. IKOULA's teams are also multilingual, in order to respond to the internationalization issues of all of its customers, located in more than 60 countries on 4 continents. Since September 2021, IKOULA has joined of the SEWAN Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom